Greenwich Lifesciences, Inc. GLSI

Annual Quarterly

No annual revenue total was found in GREENWICH LIFESCIENCES, INC.'s SEC filings.

Greenwich Lifesciences, Inc. (GLSI) files with the SEC under industry code 2834, Pharmaceutical Preparations.

Revenue
—
Net income (TTM)
$-22.47M
-19.3% vs year-ago TTM
Operating cash flow (TTM)
$-12.49M
-46.9% vs year-ago TTM
Free cash flow
—
EPS (TTM)
$-1.58
-10.8% vs year-ago TTM
Dividend per share
None
Shares outstanding
14.68M
+10.6% vs prior year
Net cash
—
Operating margin
—

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
GLSI (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Stafford, TX
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1799788

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Key figures

Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.

FY 2025
Dec 31, 2025
FY 2024
Dec 31, 2024
FY 2023
Dec 31, 2023
FY 2022
Dec 31, 2022
FY 2021
Dec 31, 2021
Operating income
-$19.4M
-$17.6M
-$9.3M
-$8.0M
-$4.6M
Net income
-$19.4M
-$17.4M
-$8.9M
-$7.8M
-$4.6M
Diluted EPS
-$1.43
-$1.34
-$0.69
—
—
Operating cash flow
-$9.9M
-$7.3M
-$6.5M
-$6.2M
-$4.3M
Total assets
$6.2M
$4.1M
$7.0M
$13.5M
$27.2M
Total liabilities
$5.8M
$3.2M
$294,406
$262,905
$385,172
Stockholders' equity
$353,217
$908,626
$6.7M
$13.2M
$26.8M
Cash and investments
$6.2M
$4.1M
$7.0M
$13.5M
$27.2M

Recent SEC filings

Form Description Filed Period
ARS Annual report to shareholders Oct 26, 2026 Dec 31, 2025
10-Q Quarterly report Aug 11, 2026 Jun 30, 2026
10-Q Quarterly report Jun 4, 2026 Mar 31, 2026
10-K Annual report Jun 1, 2026 Dec 31, 2025
8-K Current report
Shareholder vote results
 Dec 18, 2025 Dec 18, 2025
10-Q Quarterly report Nov 14, 2025 Sep 30, 2025

All 279 Greenwich Lifesciences, Inc. SEC filings

Source: SEC EDGAR filings. This is company-reported data, not investment advice.